Research programme: exportin 1-mediated nuclear export inhibitors - Karyopharm Therapeutics

Drug Profile

Research programme: exportin 1-mediated nuclear export inhibitors - Karyopharm Therapeutics

Alternative Names: CRM1-mediated nuclear export inhibitors - Karyopharm; KPT-185; KPT-350; KPT-SINE; SINE™ compounds; XPO1-mediated nuclear export inhibitors - Karyopharm

Latest Information Update: 21 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Icahn School of Medicine at Mount Sinai; Karyopharm Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; HIV infections; Inflammation; Influenza virus infections; Wounds

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Amyotrophic lateral sclerosis; Autoimmune disorders; Brain injuries; Cancer; Duchenne muscular dystrophy; Epilepsy; HIV infections; Inflammation; Multiple sclerosis; Skin disorders; Wounds

Most Recent Events

  • 22 Apr 2017 Pharmacodynamics data from a preclinical study in Duchenne Muscular Dystrophy presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 16 Mar 2017 KPT 350 is available for licensing in World as of 16 Mar 2017.
  • 16 Mar 2017 Karyopharm has patent protection for KPT 350 in countries outside USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top